CEST SESSION 2: LYMPHOMA IMAGING
DEFINING ULTRA-HIGH-RISK DLBCL PATIENTS PRIOR TO INITIAL TREATMENT BASED ON AN INTEGRATIVE HOST AND DISEASE PROGNOSTIC SCORE (FROM REMARC STUDY) abstract
C Thieblemont, J.-F Deux, L Vercellino, L Chartier, et al.
The study authors conclude that the MVED2 is the first prognostic index based on new metrics measured on 18FDG-PET and ECOG PS that may help to discriminate ultra high-risk DLBCL pts, even responder to R-CHOP.
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY. abstract
S Genta, G Ghilardi, L Cascione, D Juskevicius, et al.
The study authors conclude that their study suggests that the integration of functional PET/CT parameters and mutational profiles in prognostic models may enable a more accurate definition of individual DLBCL patient's risk.
BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL. abstract
A Gallamini, A Rambaldi, C Patti, A Romano, et al.
The study authors conclude that IPS and bTMTV > 471 ml. proved able to identify a patient subset that, despite a negative PET-2, failed ABVD treatment, thus deserving an alternative and more aggressive frontline treatment.
PROGNOSTIC ROLE OF LESION DISSEMINATION FEATURE (DMAX) CALCULATED ON BASELINE PET/CT IN HODGKIN LYMPHOMA abstract
R Durmo, A Ségolèn Cottereau, L Rebaud, C Nioche, et al.
The study authors conclude that Dmax, a PET feature reflecting the spread of the disease, is a promising prognostic factor in cHL. Combining Dmax and iPET further improves risk stratification of patients with HL and might improve the tailored therapy approach.
PREDICTIVE VALUE OF QUANTITATIVE 18F-FDG-PET-CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA. abstract
J Driessen, G. J. C Zwezerijnen, H Schöder, A. J Moskowitz, et al.
The study authors conclude that their study is the first radiomics analysis in a large cohort of r/r cHL patients. Combining radiomics and clinical features results in a strong prediction model for 3-year TTP with a tAUC of 0.90, CV-AUC of 0.79 and a vAUC of 0.77. The model uses robust PET features that address inter-lesional heterogeneity in the distance, metabolic volume, and SUV. They conclude, therefore, this model is suitable for application in clinical trials and could guide risk-stratified treatment in r/r cHL.
DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA abstract
L Ceriani, L Milan, L Cascione, G Gritti, et al.
The study authors conclude that PET-derived radiomics may improve the prediction of outcomes in DLBCL patients treated with conventional immunochemotherapy.